The CD55 Knockout SK-HEP-1 Polyclonal Cells represent a genetically modified human hepatic adenocarcinoma cell population generated through CRISPR/Cas9-mediated disruption of the CD55 gene. This product consists of a heterogeneous pool of edited cells, providing a polyclonal knockout model that avoids clonal selection artifacts and preserves the inherent phenotypic diversity of the host cell line. The targeted disruption of CD55 is designed to ablate expression of decay-accelerating factor (DAF), thereby eliminating its regulatory function in the complement cascade without introducing a defined clonal genotype. This polyclonal format is particularly suitable for studies requiring population-level assessment of complement susceptibility, immune evasion, and downstream signaling events.
The host cell line, SK-HEP-1, was originally established from the ascitic fluid of a patient with liver adenocarcinoma. It exhibits a unique combination of endothelial and epithelial characteristics, making it a versatile model for investigating hepatic tumor biology, angiogenesis, and metastatic processes. SK-HEP-1 cells are widely employed in hepatology and oncology research due to their robust growth properties and capacity to form vascular-like structures in vitro. Their dual phenotype allows researchers to explore crosstalk between epithelial-mesenchymal transition and angiogenic signaling within a malignant context, providing a clinically relevant platform for functional genomics studies.
CD55, the gene product, functions as a critical negative regulator of the complement system by accelerating the decay of C3 and C5 convertases (C4b2a and C4b2a3b, respectively). This activity prevents the downstream assembly of the membrane attack complex (MAC; C5b-9) and thereby protects host cells from complement-mediated lysis. The expression of CD55 is transcriptionally regulated by pro-inflammatory cytokines such as TNF and IL-1, the STAT3 transcription factor, and phorbol esters. Beyond its enzymatic role, CD55 interacts with the adhesion G protein-coupled receptor CD97 and binds complement components C3b and C4b. Other pathway constituents including Factor B and Factor D contribute to the amplification loop that CD55 normally constrains. By disrupting CD55, the knockout model removes this protective checkpoint, rendering cells vulnerable to opsonization and complement-dependent cytotoxicity.
In the context of SK-HEP-1 cells, which model liver adenocarcinoma, CD55 upregulation is frequently associated with immune escape and resistance to complement-mediated killing. Loss of CD55 function in this polyclonal population allows researchers to dissect how cancer cells rely on complement regulatory proteins to survive in an inflammatory microenvironment. This model becomes especially relevant for investigating paroxysmal nocturnal hemoglobinuria-related mechanisms, autoimmune pathogenesis, and the role of CD55 in viral entry, given that pathogens such as echovirus and Coxsackievirus B exploit CD55 as a cellular receptor. The resulting susceptibility to complement activation provides a functional system to assess therapeutics aiming to sensitize tumors to immune clearance.
Research applications for this knockout cell product encompass a broad spectrum of experimental workflows. Investigators can employ complement-dependent cytotoxicity assays to quantify the loss of cytoprotection, while flow cytometry and Western blotting enable verification of CD55 deficiency. Viral infectivity studies, cell viability assays, and immunofluorescence are also highly informative for characterizing CD55-dependent processes. This model supports drug development efforts targeting the complement cascade and serves as a screening tool for modulators of immune evasion. For further details or personalized support, please contact Ascent Research.
